have again been excluded from such licences and are left to try to cut deals for the most expensive products. With so many priced out of the market, global supply will again be prioritised to rich countries, while the companies refuse to make affordable generic antivirals available to everyone wherever they are needed.rich nations bought up
Meanwhile, Merck continues its “evergreening” patent strategy to extend its monopoly on molnupiravir beyond the standard 20-year protection. Since developing the pill, it has sought at least 53 patent applications to tie it up in legal red tape and stay firmly in control of who gets to make it and where.
Problem is when licenses are doled out to less developed countries they end up in hands of cronies and govt endorsed criminals in those countries